Abstract |
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.
|
Authors | P J Reading, A K Luce, I G McKeith |
Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 16
Issue 6
Pg. 1171-4
(Nov 2001)
ISSN: 0885-3185 [Print] United States |
PMID | 11748755
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2001 Movement Disorder Society. |
Chemical References |
- Carbamates
- Neuroprotective Agents
- Phenylcarbamates
- Rivastigmine
|
Topics |
- Aged
- Carbamates
(therapeutic use)
- Caregivers
(psychology)
- Cognition Disorders
(drug therapy, etiology)
- Female
- Follow-Up Studies
- Hallucinations
(drug therapy)
- Humans
- Male
- Middle Aged
- Neuroprotective Agents
(therapeutic use)
- Parkinson Disease
(psychology)
- Phenylcarbamates
- Psychotic Disorders
(drug therapy, etiology)
- Rivastigmine
- Stress, Psychological
- Treatment Outcome
|